First, nine years in remission is a remarkable achievement — that's something to hold onto. A relapse is understandably frightening, but the fact that it appears localized to the neck nodes is an encouraging sign.
When mantle cell lymphoma (MCL) returns, there are several treatment options that an oncologist may consider Show Full Answer
First, nine years in remission is a remarkable achievement — that's something to hold onto. A relapse is understandably frightening, but the fact that it appears localized to the neck nodes is an encouraging sign.
When mantle cell lymphoma (MCL) returns, there are several treatment options that an oncologist may consider, especially for relapsed disease:
- Targeted therapies like acalabrutinib (Calquence), zanubrutinib (Brukinsa), or pirtobrutinib (Jaypirca)
- Venetoclax (Venclexta), sometimes used off-label
- Immunotherapy combinations such as lenalidomide plus rituximab
- CAR T-cell therapy, such as brexucabtagene autoleucel (Tecartus) or lisocabtagene maraleucel (Breyanzi)
- Previously unused chemotherapy regimens Since the disease appears limited to the neck nodes, this may open up additional options like radiation therapy, which is sometimes used for more localized disease.
Newer treatments continue to improve outcomes for relapsed MCL, and clinical trials are also worth exploring with your oncologist, as they may offer access to cutting-edge therapies.
Connecting with others on MyLymphomaTeam who've navigated a relapse can also provide real-world insight and emotional support from people who truly get it.
June 2
Continue with Facebook
Continue with Email
Join
Your Privacy Choices
